The three-fingered salute from The Hunger Games has become a popular sign of resistance in Thailand to the military-backed government
With unions unable to muster large numbers, labor groups experiment with a different kind of strike
The regional Fed bank is exempt from the Freedom of Information Act, for one thing
Tech companies are pleading for more visas to address a problem scholars say they made up
It's far easier for the rich to move from country to country. When they go, why should they get to take all the money they've accumulated by virtue of living here?
Twist, stretch, twirl: a day in the life of a candy cane
Students who admit to sexual assault “deserve some consideration,” a UVA administrator said in a video interview
Few small businesses have a real, rational marketing budget. Here’s why that’s OK
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.